Onyx is advancing a robust pipeline of innovative investigational therapies targeting several molecular pathways in cancers, with the goal of extending and enhancing the lives of patients.
The goal of the development program for carfilzomib, a proteasome inhibitor currently approved in the U.S. for one type of multiple myeloma, is to further evaluate the drug’s efficacy and safety both as a single-agent and in combination with other therapies across the spectrum of multiple myeloma disease states. Multiple clinical trials evaluating carfilzomib either as a single-agent or in combination with other therapies for the treatment of patients with multiple myeloma are currently ongoing.
Earlier Stage Pipeline
In addition to carfilzomib, our proteasome inhibitor program includes oprozomib, an oral proteasome inhibitor currently in Phase 1b/2 clinical testing.